目的 評(píng)價(jià)丹參川芎嗪注射液聯(lián)合常規(guī)用藥治療心力衰竭的療效和安全性。方法 系統(tǒng)地檢索Cochrane Library、Pubmed、Web of Science、Embase、萬方數(shù)據(jù)庫（Wanfang）、中國學(xué)術(shù)期刊全文數(shù)據(jù)庫（CNKI）、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫（SinoMed）和維普中文期刊全文數(shù)據(jù)庫（VIP）中丹參川芎嗪注射液聯(lián)合常規(guī)用藥治療心力衰竭的隨機(jī)對(duì)照研究（RCT）。檢索時(shí)限從建庫至2018年12月6日，提取資料，并使用Review Manager 5.3軟件進(jìn)行Meta-分析。結(jié)果 共納入18項(xiàng)RCTs，共1 548例患者。Meta-分析結(jié)果顯示：丹參川芎嗪注射液聯(lián)合常規(guī)用藥在臨床療效［OR=3.33，95% CI （2.39～4.63）， P<0.000 01］、提升射血分?jǐn)?shù)［SMD=1.05， 95% CI （0.27～1.83）， P=0.009］、下調(diào)B型腦鈉肽（BNP）水平［SMD=-1.22，95% CI（-2.03～-0.41），P=0.003］、升高每搏排血量［SMD=1.28，95% CI（0.19～2.38），P=0.02］和心臟指數(shù)［SMD=1.44，95% CI（0.50～2.38），P=0.003］方面均優(yōu)于常規(guī)用藥組，未見明顯不良反應(yīng)。結(jié)論 丹參川芎嗪注射液聯(lián)合常規(guī)用藥治療心力衰竭療效優(yōu)于常規(guī)用藥，但由于納入研究樣本量較少、文獻(xiàn)質(zhì)量較低，其治療心力衰竭的療效需要更多高質(zhì)量的臨床研究加以證實(shí)。

Objective To evaluate the efficacy and safety of Salvia Miltiorrhiza Ligustrazine Injection combined with conventional drugs in the treatment of chronic heart failure. Methods Systematic search of Cochrane Library, Pubmed, Web of Science, Embase, Wanfang database, China Academic Journal Full-text Database (CNKI), China Biomedical Literature Database (SinoMed) and Weipu Chinese Journal Full-text Database (VIP). Search the randomized controlled trial (RCT) about Salvia Miltiorrhiza Ligustrazine Injection combined with conventional drugs in the treatment of chronic heart failure. The search date was from the establishment of the database to December 6, 2018. The data was extracted and Meta-analysis was performed using Review Manager 5.3 software. Results A total of 1 548 patients were included in 18 RCTs. Meta-analysis. results Salvia Miltiorrhiza Ligustrazine Injection combined with conventional drugs in clinical efficacy[OR=3.33, 95%CI(2.39-4.63), P<0.000 01], elevated ejection fraction[SMD=1.05, 95%CI(0.27-1.83), P=0.009], lower BNP levels[SMD=-1.22, 95%CI(-2.03--0.41), P=0.003], elevated blood intake per beat (SMD=1.28, 95%CI(0.19-2.38), P=0.02] and heart index[SMD=1.44, 95%CI(0.50-2.38), P=0.003], and other aspects are superior to the conventional drug group, no obvious adverse reactions. Conclusion The efficacy of Salvia Miltiorrhiza Ligustrazine Injection combined with conventional drug treatment is better than conventional drug use, but because the small sample size and lower literature quality in the stud, the curative effect of Salvia Miltiorrhiza Ligustrazine Injection in the treatment of heart failure needs more high-quality clinical research to confirm.

河北省科技廳健康醫(yī)療與生物醫(yī)藥專項(xiàng)（18277783D）